-
09/15/25 Health Advisory: 2025–2026 respiratory-illness season vaccine recommendations
Summary Influenza COVID-19 RSV Co-administration of COVID-19, flu, and RSV vaccines is safe. Vaccination is one of the best ways to prevent severe disease and hospitalization. COVID-19 vaccine recommendations and Washington State Department of Health (DOH) support evidence-based recommendations from trusted national medical specialty societies, including the American Academy of Pediatrics (AAP), the American Academy…
-
04/08/22 Health Advisory: COVID-19 Information for Providers
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, News and Alerts, Notifiable Conditions, Provider ResourcesRequested actions Be aware, on March 29, 2022, Food and Drug Administration (FDA) amended its emergency use authorization (EUA) for Moderna COVID-19 booster dose vaccine. A new multi-dose vial is now available. It has a dark blue cap and a label with a purple border. Doses from this vial are 0.5 mL. Multi-dose vials are…
-
4.1.22 WCHD Provider Advisory~ COVID Therapeutics
Requested Actions Be aware, the Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup have endorsed the Food and Drug Administration (FDA) emergency use authorization of a second booster dose of either the Pfizer-BioNTech (Pfizer) or Moderna COVID-19 vaccines for specific groups. These second boosters are particularly important for people…
-
03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups
Advisory or Update, Communicable Disease and Immunization Update, Health Advisory, News and Alerts, Notifiable Conditions, Provider ResourcesRequested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup endorsed Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) of a second booster dose of Pfizer or Moderna COVID-19 vaccines for specific groups. The EUA allows: A second booster dose of Pfizer COVID-19 vaccine at least…
-
03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Immunizations, MERS-CoV, Notifiable Conditions, Novel Coronavirus, Provider Resources, VaccineRequested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email…
-
03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Advisory or Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesRequested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email…
-
03/01/2022 Provider Alert: UPDATE – COVID-19 Therapies
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Health Alert, MERS-CoV, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, SchoolsRequested Actions Be aware, providers should contact and re-dose patients who previously received the 150mg Evushield dose (see below) Be Aware, supply of COVID-19 therapeutics is not currently limited in Whatcom County. While COVID-19 case rates are decreasing in Whatcom County, some patients may benefit from therapeutics. Decision to prescribe should be based on clinical…
-
02/25/22 Health Advisory: COVID-19 Updates for Providers
Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a…
-
02/16/22 Health Advisory: CDC Updated COVID-19 Vaccination Guidelines, and More.
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Immunization, Immunizations, Infection Control, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, VaccineRequested Actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster dose 3 months (instead…
-
02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster…
-
02/02/22 Health Advisory: FDA Provides Full Approval For Spikevax
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Immunization, Immunizations, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, Schools, VaccineRequested Actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use authorization (EUA) Moderna COVID-19…
-
02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Notifiable Conditions, Provider Resources, UncategorizedCOVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use…
-
01/08/22 Health Advisory: CDC updated Antiviral Guidance; Booster Eligibility Expanded
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Alert, Immunization, Infection Control, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, Schools, Vaccine, WCHD Epi WatchCOVID-19 Updates for Providers Requested actions Updated Antiviral Guidance Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit…